Careers  |  Sign In  |  Register  |   Twitter

Possible Treatment for Juvenile Idiopathic Arthritis

Because interleukin-6 plays a pathogenic role in systemic juvenile idiopathic arthritis (JIA), a new study in The New England Journal of Medicine investigates the effect of anti-interleukin-6 receptor antibody tocilizumab in a double-blind phase. The primary end point was met in significantly more patients in the tocilizumab group than in the placebo group at week 12, when there was an absence of fever and an improvement of 30% or more on at least three of the six variables, with no more than one variable worsening by more than 30%. While tocilizumab was effective in relieving JIA symptoms, adverse effects occurred more frequently in the tocilizumab group.

Read it in The New England Journal of Medicine.